Biocon share price: Shares of Biocon Ltd rose 3% after Biocon Pharma received FDA approvals for cancer drugs Lenalidomide and Dasatinib, enhancing its US oncology market presence. The company also got tentative approval for Rivaroxaban. Despite recent stock declines, analysts suggest a potential 22% upside. Biocon’s Q3 profits dropped sharply due to a previous one-time gain.
ETMarkets Smart Talk: Fixed income attractive with rate cuts ahead; 20–40% allocation advisable for risk hedge, says Tanvi Kanchan
Amidst market volatility, Anand Rathi’s Tanvi Kanchan suggests a 20%-40% fixed income allocation for portfolio stability. She anticipates a stock-specific market in FY26, driven by
July 15, 2025